Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

394
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
394
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

457
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
457

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinically aligned rationale generation for glaucoma subtype classification via a knowledge-distilled language model.

medRxiv : the preprint server for health sciences·2026
Same author

Childhood Angle Closure: Etiology and Treatment Outcomes from a Large Series Spanning over 20 Years.

Ophthalmology. Glaucoma·2026
Same author

Outer nuclear layer hyperreflectivity as an optical coherence tomography finding in Danon disease.

Acta ophthalmologica·2026
Same author

Clinically informed semi-supervised learning improves disease annotation and equity from electronic health records: a glaucoma case study.

NPJ digital medicine·2025
Same author

Clinically Informed Semi-Supervised Learning Improves Disease Annotation and Equity from Electronic Health Records: A Glaucoma Case Study.

Research square·2025
Same author

Clinically Informed Semi-Supervised Learning Improves Disease Annotation and Equity from Electronic Health Records: A Glaucoma Case Study.

medRxiv : the preprint server for health sciences·2025
Same journal

Drug-associated lacrimal drainage obstruction: a population-based pharmacovigilance study.

Orbit (Amsterdam, Netherlands)·2026
Same journal

Re: "A new surgical technique for excision of orbital cavernous hemangioma: a 15-year experience".

Orbit (Amsterdam, Netherlands)·2026
Same journal

Study of the toxic effect of benzalkonium chloride on epithelial cells of the lacrimal canaliculi.

Orbit (Amsterdam, Netherlands)·2026
Same journal

Orbital venous-flow malformations: is terminology complicating management in the <i>AI</i> era?

Orbit (Amsterdam, Netherlands)·2026
Same journal

Response to teprotumumab in thyroid eye disease patients of long duration and high clinical activity score.

Orbit (Amsterdam, Netherlands)·2026
Same journal

Incidentally discovered asymptomatic extramedullary plasmacytoma involving the orbit and dura.

Orbit (Amsterdam, Netherlands)·2026
See all related articles

Related Experiment Video

Updated: Nov 28, 2025

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

181

Fedratinib-induced orbital inflammation.

John Y Lee, Ryan A Gallo, Daniel M Vu1

  • 1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.

Orbit (Amsterdam, Netherlands)
|November 27, 2020
PubMed
Summary
This summary is machine-generated.

Fedratinib, a myelofibrosis treatment, may cause orbital inflammation and cellulitis. Ophthalmic symptoms resolved after discontinuing the medication, suggesting a drug-related adverse event.

Keywords:
Drug side effectJAK2 inhibitorfedratiniborbital inflammation

More Related Videos

Three-Dimensional Reconstruction of Orbital Fractures
08:18

Three-Dimensional Reconstruction of Orbital Fractures

Published on: May 16, 2025

479
Retro-orbital Injection in Adult Zebrafish
04:50

Retro-orbital Injection in Adult Zebrafish

Published on: December 7, 2009

25.5K

Related Experiment Videos

Last Updated: Nov 28, 2025

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

181
Three-Dimensional Reconstruction of Orbital Fractures
08:18

Three-Dimensional Reconstruction of Orbital Fractures

Published on: May 16, 2025

479
Retro-orbital Injection in Adult Zebrafish
04:50

Retro-orbital Injection in Adult Zebrafish

Published on: December 7, 2009

25.5K

Area of Science:

  • Ophthalmology
  • Hematology
  • Pharmacology

Background:

  • Myelofibrosis is a serious bone marrow disorder.
  • Fedratinib is a Janus kinase (JAK) inhibitor used to treat myelofibrosis.

Observation:

  • A 69-year-old male with myelofibrosis developed left periorbital swelling, blurred vision, and orbital pain.
  • Clinical examination revealed restricted extraocular motility, conjunctival injection, chemosis, and periorbital edema.
  • MRI indicated orbital cellulitis.

Findings:

  • The patient initiated fedratinib therapy two weeks prior to symptom onset.
  • Symptoms recurred on the contralateral side upon restarting fedratinib.
  • A temporal association was established between fedratinib use and the onset of ophthalmic symptoms.

Implications:

  • Fedratinib may be associated with orbital cellulitis as a potential adverse effect.
  • Prompt recognition and discontinuation of fedratinib can lead to rapid symptom resolution.
  • This case highlights the importance of considering drug-induced orbital inflammation in patients receiving fedratinib.